Clinical Trials
- Breast Cancer, Lung Cancer
A Phase 1, Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 and ABBV-368 With and Without ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors
- Date01/12/2020
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Head and Neck Cancers, Kidney Cancer, Leukemia, Lymphoma, and Myeloma, Liver Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Phase 1 Cancers, Prostate Cancer, Stomach and Esophagus, Thyroid and Other Endocrine Cancers
A Phase 1b Dose-Escalation Study of Cabozantinib (XL184) Administered Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
- Date07/04/2019
- Breast Cancer
A Phase 2 Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Pretreated Metastatic Triple Negative Breast Cancer
- Date12/22/2019
- Breast Cancer
A Phase I, Open-Label Study of D-0502 Single Agent and D-0502 in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer
- Date02/19/2020
- Breast Cancer, Gynecological Cancers
A Phase I/IIa, Open-Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Ascending Doses of AZD7648 Monotherapy or in Combination With Either Cytotoxic Chemotherapies or Novel Anti-Cancer Agents in Patients With Advanced Malignancies
- Date01/22/2020
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Gynecological Cancers, Head and Neck Cancers, Kidney Cancer, Lung Cancer, Melanoma, Phase 1 Cancers, Stomach and Esophagus
A Phase Ia/Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MTIG7192A as a Single Agent and in Combination With Atezolizumab in Patients With Locally Advanced or Metastatic Tumors
- Ages18 years and older
- GenderBoth
- Date06/28/2016
- Breast Cancer, Phase 1 Cancers
A Phase II Multiple-Arm, Open-Label, Randomized Study of PARP Inhibition (Veliparib; ABT-888) and Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) Either Alone or in Combination in Homologous DNA Repair (HDR) Deficient Triple Negative Breast Cancer (TNBC)
- Date05/10/2017
- Breast Cancer
A Phase III Multi-center, Randomized, Open-label Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as an Adjuvant Treatment in Patients With Hormone Receptor-positive, HER2-negative Early Breast Cancer (New Adjuvant TriAl With Ribociclib [LEE011]: NATALEE)
- Date05/21/2019
- Breast Cancer
A Randomized Phase II Study to Evaluate Efficacy of T-DM1 With or Without Palbociclib in the Treatment of Patients With Metastatic HER2 Positive Breast Cancer
- Date01/21/2019
- Breast Cancer
A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
- Date02/10/2019